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Sickle cell disease (SCD), also known as sickle cell anemia (SCA) is one of the structural hemoglobinopathies that
occurs due to a single nucleotide mutation from GAG to GTG, which changes the amino acid of a β-globin chain of
hemoglobin (Hb) from glutamate to valine. This singular mutation results to disorderliness in red blood cells
(RBCs) with advent of changes in RBC morphology and other pathological conditions. In the 1980s, intermittent
red blood cell transfusions, opioids, and penicillin prophylaxis were the only available therapy for SCA and were
commonly reserved for acute, life threatening complications. So far, the US Food and Drug Administration (FDA)
has granted a total of four drugs approval for the prophylaxis and treatment of the clinical complications of SCD.
Due to limitations (adherence, safety, adverse effects) of existing therapies in the prophylaxis and treatment of
SCD complications in Nigerian children and their inaccessibility to approved drugs, the present study discusses
the therapeutic effects of readily available functional food as one of the therapies or an adjunct therapy to tackle
the sickle cell crisis in Nigerian Children.

1. Introduction
Sickle cell disease (SCD) is a group of genetic ailments affecting the
red blood cell [1]. It is sometimes referred to as drepanocytosis consisting
of sickle thalassemia and sickle cell anemia (HbSS). Heterozygous genotypes (HbAS) expressing parents are sickle cell carriers and their
offspring have 25 % chances of giving rise to a homozygous sickle genotype (HbSS) progenies or a 75 % homozygous normal genotype
(HbAA) [2]. Sickle cell derangement was ﬁrst identiﬁed as a hematological disease by Herrick in 1910 [2] and its biochemical pathology was
proven by Linus Pauling in 1949 [2]. Epidemiological information on
SCD has majorly been reported among Jamaica, India and US population,
with less statistics in Africa where the trait of SCD is said to be largest [3].
It is mostly common among the black Africa, and some other races
occupying the Mediterranean, India, and Middle East [4]. Further studies
on children born with SCD have recorded the major occurrence in the
developing world, with an estimated 200,000 annual sickle genotype
births in Sub-Saharan Africa [5].

Sickle cell disease is one of the causes of childhood mortality in Africa. 80% of people with SCD globally live in Sub-Saharan Africa. This
proportion is projected to reach 88% by 2050 [6,7]. Nigeria has the
largest burden of sickle cell disease in Africa and the world, with
approximately 150,000 births annually [8] and 50–90% of them die
before age ﬁve [9]. Poor quality healthcare, poor education, unawareness, poverty, and poor nutritional choices contribute to excess mortality.
In West African for example, historical and scientiﬁc records have
described different names used to qualify SCD children among the three
main Nigerian tribes. The Yorubas, constituting the dominant population
in the west called them “abiku” translated “sufferers'' or “children that
bring sadness” [10, 11], the Ibos called them “Ogbanje” [12], and the
Hausas called them “Sankara-miji” [13]. It is the major innate disorder in
Nigeria, affecting about 4 million population at prevalence of 2% at birth
while more than 40 million persons have sickle cell traits.
Nigeria shows a record for about 75% of children with SCD in Africa
[14]. Though having normal weight at birth, babies affected by SCD
show weight loss during the ﬁrst year and gradually lingers until
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Polyphenols, alkaloids, ﬂavonoids, and other Phenolic compounds
have been reported [21] to have antisickling and antioxidant effects
which are capable of restoring normalcy to the titled redox balance that
originally contributes to sickle cell crisis in children. Such foods containing polyphenols are often referred to as functional foods i.e. foods
containing bioactive compounds that can promote the health of a person
beyond rudimentary diets, or serve as a measure for prevention or
management of chronic diseases [22].
Nevertheless, the application of renowned drugs and potential curative treatments will most likely be limited to high-income countries who
are able to possess them at high cost, leaving out the low – income
countries with severe complications due to unavailability of these therapeutics (Table 1). In this review, we discuss the readily available unique
functional foods that can be used in ameliorating the sickle cell crisis in
Nigerian Children.

adulthood incidentally followed by prolonged skeletal maturation in
both boys and girls with a protracted menarche in girls [15]. At molecular and genetic levels, the hereditary sickle cell derangement is visualized when a single nucleotide base substitution occurs in the gene coding
human β-globin subunit. Such substitution causes the replacement of
hydrophilic amino acid (glutamic acid) at position 6 in normal hemoglobin (HbA) by a hydrophobic amino acid (valine) in abnormal hemoglobin, culminating in the disease state of sickle red cells [16]. The
occurred hydrophobic replacement results in insolubility of sickle cell
hemoglobin (HbS) when deoxygenated. HbS molecules that are
constantly formed polymerize to long crystalline intracellular mass of
ﬁbers that deform the original biconcave shape of the red blood cell
(erythrocyte) into a sickled shape cell. The magnitudes of this reshaping
are noticed with hemolytic anemia and tissue disruption emanated from
the blockage of blood vessels by the sickled cells.
Clinical appearances of this condition are vascular necrosis, hyposthenuria, proliferative retinopathy, priapism, aplastic crises, pulmonary
disease and nephropathy. In most cases, the complications are severed
and include periodic attacks of pain and progressive organ dysfunction
leading to a much reduced biologic life span [17]. Likewise, reactive
oxygen species [18] are considered to play a crucial role in the SCD
pathogenesis. The chronically increased oxidative stress in SCD might
play a signiﬁcant role in the emergence of SCD related organ complications [19].
Pharmacologically, many drugs with various targeted pathways have
emerged. However, majority of them have failed to display beneﬁt in
medical trials, few have produced encouraging results but with less
availability making them out of reach for low – income countries like
Nigeria [20]. According to WHO (2002), up to 80% of individuals living
in Africa depend on traditional plant-based treatment, with slight side
effects, for their primary health care needs [18]. Phytomedicine has been
widely utilized as effective remedies for the prevention and treatment of
multiple health conditions for centuries by almost every known culture in
Nigeria [18].

2. Pathophysiology of Sickle Cell Disease
Sickle cell disease (SCD), also known as sickle cell anemia (SCA) is
one of the structural hemoglobinopathies that occurs due to a single
nucleotide mutation from GAG to GTG, which changes the amino acid of
a Beta-globin chain of Hb from glutamate (hydrophilic) to valine (hydrophobic). This mutation is a point mutation, and it occurs at the 6th
position or codon on the Beta-globin chain [23]. This single action produces an abnormal globin chain and is responsible for the unique properties of a sickle cell (Figure 1). The pathophysiology of sickle cell anemia
entails four different parts occurring in a vicious cycle: (1) polymerization, (2) hemolysis, (3) vaso-occlusion, and (4) sterile inﬂammation
(Figure 2) [24,25].
2.1. Polymerization
When the red blood cell (RBC) of a sickle patient becomes deoxygenated, it presents a sticky patch on its surface and tends to stick to other

Table 1. Clinical trials of the FDA approved pharmaceutical drugs for sickle cell disease.
Clinical Trials

Mechanisms and Results

Recommended Dosage & Cost

Side Effects

Hydroxyurea
Multicenter Study of
Hydroxyurea (MSH)
NCT00000586 [54]
Multicentre, randomised,
controlled trial (BABY HUG)
NCT00006400 [55]

Targeting HbS polymerization: Inhibits
Ribonucleotide reductase; thereby increasing HBF
levels, which in turn retard sickling.
Drug was well tolerated. Reduction in the need for
blood transfusions and frequency of painful
episodes, lower hospitalization rates, and reduced
number of episodes of acute chest syndrome in
children and adults.

Start with 15 mg/kg/day and then gradually
increase the dose by 5 mg/kg/day every 4- to 8weeks until it reaches the maximum tolerated dose
(MTD) which is 30–35 mg/kg/day. ICER estimated
the annual costs of Hydroxyurea to be $1,200.

Thinning hair (mild hair loss),
dermatologic changes (skin
hyperpigmentation or dark ﬁngernail
beds), and nausea. There are chances
for HU to increase embryofetal
toxicity, low sperm count, and
myelosuppression [77, 78].

L-glutamine
Phase III randomized trial
NCT01179217 [69]

Targeting hemolysis-mediated endothelial
dysfunction: Increase NADH and NAD redox
potential; thereby maintaining vascular tone &
impairing adhesion.
Drug was well tolerated; reduction in the number of
pain crises, lower hospitalization rates, and reduced
number of episodes of acute chest syndrome in
children and adults with SCD with or without
hydroxyurea compared to those that received
placebo. No improvement in Hb or reticulocyte
count.

0.3 g/kg glutamine powder is administered orally
twice per day. The estimated cost is above $3000/
month for adults and $1000/month for children,
which is 20 times more expensive than hydroxyurea
[65]. The estimated annual cost is $24,000 [ICER].

Nausea, headache, constipation,
cough, and abdominal pain

Crizanlizumab
Phase II randomized trial
NCT01895361 [70]

Targeting vasocclusion: Humanized monoclonal
antibody against P-selectin; thereby reducing pain
crises.
All SCD genotypes experienced tremendous
reduction in the percentage of crisis episodes by
45% in high-dose arm; no improvement in markers
of hemolysis.

5 mg/kg is administered intravenously over a
period of 30 min at weeks 0, and 2, followed by 5
mg/kg once every 4 weeks. 100mg cost $2828.6
while the annual costs is estimated to be $88,000
[ICER].

Nausea, arthralgia, back pain, and
pyrexia

Voxelotor (Oxbryta/
GBT440)
1/2, RDBPC, NCT02285088/
NCT03041909 [74]
Phase III randomized trial
NCT03036813 [75]

Targeting HbS polymerization: Binds to HbS aglobin chain and stabilizes it in the R-state; thereby
increasing its afﬁnity for oxygen.
Voxelotor was well tolerated. Signiﬁcant
improvement in hemoglobin levels and markers of
hemolysis.

1500mg once daily. Voxelotor is available as a 500mg oral tablet, and its estimated cost is $138.89 per
tablet [76] while its annual cost is $84,000 [ICER].

Headache, diarrhea, nausea, and
arthralgia
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Figure 1. Schematic of RBC sickling in the vasculature: (a) point mutation from GAG to GTG cause a normal adult hemoglobin HbA to become sickle HbS (b) OxyHbS
takes a sickle or banana shape after deoxygenation and polymerizes to form (3) HbS ﬁber, leading to vaso-occlusion. However, some HbS molecules, with the sickle
shape (DeoxyHbS) manage to escape polymerization and undergo reoxygenation and revert back to OxyHbS (desickling). Multiple cycles of sickling and desickling
predisposes HbS molecules to hemolysis leading to hemolytic anemia [1, 26].

endothelial dysfunction. In addition, in the process of hemolysis, arginase is being released intravascularly from the destructed sickle red
blood cells. Arginase reduces nitric oxide (NO) bioavailability by
consuming plasma arginine levels (the latter being an important substrate for nitric oxide (NO) synthases), thereby, aggravating NO
depletion and further damaging the endothelial NO-sustained mechanisms of vasodilation [27, 28].

hemoglobin molecules to form a polymer of mutated sickle cell hemoglobin (HbS) molecules. The polymers then aggregate to form an insoluble, long chain of rigid ﬁber (bundle) that distort and modify the RBC
membrane resulting in sickling. Piccin and colleagues [27] reported that
valine hydrophobicity is responsible for this sickling because it attracts
hydrophobic regions of adjacent β-chains during polymerization. This
sickling property (Figure 1) is the trademark that leads to the downstream of events -hemolysis, vaso-occlusion, and sterile inﬂammation,
including the manifestations of a sickle RBC.

Endothelial enzymes ➝ O2⋅– þ NO ➝ ONOO-

During oxygenation and deoxygenation, the sickled red blood cells
become fragile and prone to rupture (hemolysis) probably due to loss of
their membrane ﬁlaments leading to anemia. This portrays the short
lifespan of 10–20 days seen in a sickle cell as opposed to the 100–120
days in a normal RBC. The premature destruction of HbS RBC (hemolysis) has been shown to mediate endothelial dysfunction by releasing cellfree hemoglobin molecules into the blood. The hemoglobin molecules in
their oxygenated state of Fe2þ oxidize to form methemoglobin (Fe3þ), a
non–oxygen-binding form of hemoglobin with inert nitrate (NO3) and
hydroxyl free radical (OH⋅) as shown in the reaction given below.

Similarly, endothelial enzymes such as xanthine oxidase, uncoupled
endothelial NO synthase, and NADPH oxidase that are produced via
catalysis by hemoglobin and heme including damaged tissues, neutrophils, and platelets also contribute to the endothelial dysfunction through
the production of superoxide anion radical (O2⋅–) that depletes endothelial NO to produce peroxynitrite (ONOO-). Several studies [28, 29]
have shown that these ROS originates from numerous sources, and sickle
RBCs have an impaired ability to neutralize them due to their reduction
of endogenous antioxidants. Subsequently, methemoglobin (Fe3þ)
breaks down to release cell-free heme giving rise to erythrocyte
damage-associated molecular pattern (eDAMP). The eDAMP destructs
redox balance of the cell, and promotes oxidative stress and sterile
inﬂammation.

1) Fe2þ þ NO ➝ NO3 þ Fe3þ deoxygenation reaction

2.3. Vaso-occlusion

2.2. Hemolysis

2) Fe2þ þ H202 ➝ OH⋅ þ Fe3þ Fenton reaction

Past and current studies have indicated the interplay among HbS
polymerization, impaired blood rheology, hemolysis, and increased
adhesiveness of sickle RBCs with inﬂammatory cells and vascular endothelium, and vaso-occlusion activation. However, the cellular and molecular mechanism of action of vaso-occlusion still remains uncertain.

In the equation one above, the cell-free Hb scavenges and transforms
NO into nitrate. NO impairs a myriad of adhesion molecules and
maintains platelets in steady state, thus preventing endothelial damage.
Hence, depletion of NO by free Hb would invariably promote
3

O.J. Alabi et al.

Heliyon 8 (2022) e09630

Figure 2. Pathophysiology of sickle cell disease. Adapted from [24].

vaso-occlusion. In an attempt to compensate for blood shortage during or
following hemolysis, the bone marrow produces more reticulocytes than
normal, therefore, it becomes stressed and produces immature reticulocytes, known as “stress reticulocytes” with adhesion moleculesα4β1 integrin (VLA-4) and CD36 expressed on their surface [1, 31, 39].

Also, evidence has shown that blood vessels occlusion can be initiated by
diverse mechanisms involving different inﬂammatory and/or environmental stimuli such as TNFα, hypoxia, heme, dehydration, Hb, infection,
hypoxia, acidosis, lipopolysaccharide, and several others [30, 31, 32, 33,
34]. It has been reported that these stimuli or triggers may cause pain
events due to a link or connection between the vaso-occlusion and
autonomic nervous system [35]. Further, it has been explained that the
cellular and molecular paradigm of vaso-occlusion is not similar in all
vascular beds or organs [24].
After deoxygenation, the HbS bundle takes a sickle or needle-like
shape that protrudes through the lipid bilayer to cause a leakage [36],
which causes the inﬂux of calcium ions inside the HbS. This action activates the HbS RBC ion channel (Ca2-dependent K channel, K–Cl
cotransport) resulting in a corresponding efﬂux of potassium ion and
water out of RBC [27, 37]. This further distorts the RBC and makes the
RBC more viscous and dehydrated. The HbS polymer bundles also
stimulate membrane lipids peroxidation to cause the release of peroxidation products which can damage the membrane structure, alter water
permeability, and increase cell deformability. Disruption of the RBC
membrane phospholipids causes the exposure of phosphatidylserine (PS)
to the outer cell surface [38]. This loss in RBC integrity makes it
detectable and markable by macrophages and spleen for destruction,
thereby elevating the level of hemolysis, and thus contributing to chronic
anemia. Most destruction of sickle hemoglobin takes place extracellularly, while only a fraction occurs intravascularly and make up 30% of
total hemolysis [36]. During hemolysis, heme is produced. Hemolysis,
heme, and dehydration have been indicated to propagate or contribute to

2.4. Sterile inﬂammation
The sterile inﬂammation pathway has been indicated to be activated
by a concerted action of both hemolysis-mediated endothelial dysfunction and increased adhesion-mediated vaso-occlusion [24, 40, 41]
(Figure 2). Either of the cell-free heme or ischemia-reperfusion (I-R)
injury promotes sterile inﬂammation in SCA by activating the inﬂammasome pathways in vascular and inﬂammatory cells to release Interleukin-1β (IL-1β). The released or activated IL-1β aggravates the
progression of vaso-occlussion by promoting the adhesiveness of platelets, neutrophils, and endothelial cells, upregulation of P-selectin,
E-selectin, intercellular adhesion molecule-1 (ICAM-1), vascular cell
adhesion molecule-1 (VCAM-1), and chemokines [28, 42]. In the process
of inﬂammasome activation, heme and I-R injury have been shown to be
involved in the generation of reactive oxygen species (ROS), neutrophil
extracellular trap (NET), generations of DAMPs, and DNA, and activation
of the Toll-like receptor 4 (TLR4) [40,43,44,45,46,47]. In other words,
ROS, NET, TLR4, DAMPs, and DNA play a critical role in Inﬂammasomes
activation following their stimulation and/or generation by heme or I-R
injury. Therefore, deletion/inhibition of any of these molecules might
prevent or attenuate sterile inﬂammation in SCD.
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3. FDA approved pharmaceutical drugs for sickle cell disease in
clinical practice

L-glutamine is not fully understood, although it has been associated with
the protection against RBC oxidative damage (Figure 5). L-Glutamine is
an amino acid and precursor required in the synthesis and production of
glutamate (Glu), glutathione (GSH), arginine (Arg), and nicotinamide
adenine dinucleotide (NADH), all of which protect the RBC from oxidative damage and indirectly maintain vascular tone [65]. NADH/NADPH
is an oxidative reductant that plays a critical role in maintaining the
redox potential of the cell. It helps to regenerate and recycle reduced
glutathione (GSH) which is essential for the detoxiﬁcation of hydroxyl
radicals (OH⋅) and hydrogen peroxides (H202). The combined activities
of NADPH and GSH help to mop up endogenous ROS, stabilize and
protect the RBC against oxidative damage or stress. Additionally, the
production of arginine plays a signiﬁcant role in Nitric Oxide (NO) production thus, enhancing NO bioavailability and preventing endothelial
dysfunction.
A study demonstrated by Morris and colleagues [66] in SCD patients
showed a signiﬁcant reduction in total glutathione and glutamine levels
compared to normal healthy individuals. The depletion of glutamine
levels was freely associated with pulmonary hypertension and contributed to RBC membrane damage and endothelial adhesion. Further, in the
past and recent studies of Niihara and colleagues, L-glutamine therapy administered orally - improved the redox potential of sickle RBC and
showed a signiﬁcant reduction in the endothelial adhesion of sickle cells
to the human endothelial cells of the umbilical vein [67, 68]. In a phase 3
trial (Table 1), L-glutamine demonstrated a reduction in the number of
pain crises, lower hospitalization rates, and reduced number of episodes
of acute chest syndrome in children and adults with SCD with or without
hydroxyurea compared to those that received placebo [69]. Nevertheless,
none of these studies shows any improvements in Hb or reticulocyte
count.

So far, the US Food and Drug Administration (FDA) has granted a total
of four drugs approval —Hydroxyurea, L-glutamine, voxelotor, and crizanlizumab—for the prophylaxis and treatment of the clinical complications of SCD. In the 1980s, intermittent red blood cell transfusions
were the only available therapy for SCA and were commonly reserved for
acute, life threatening complications [48]. Blood transfusions were
claimed to be associated with a number of risks, including acute transfusion reactions, transmission of infection, the development of allo- and
auto-antibodies to erythrocyte and human leukocyte antigens, and
transfusional hemosiderosis (iron overload) leading to further damage to
organs such as the heart, pancreas, and liver [49, 50]. In addition, there
are other supportive therapies such as hydration and opioids analgesics
that are commonly used along with blood transfusion to manage the
painful events of sickle cell disease.
3.1. Hydroxyurea (hydroxycarbamide)
In the 1990s, hydroxyurea (HU) emerged as a promising pharmacologic therapy for SCA [48] and was approved for use in adults with SCD
by the US Food and Drug Administration in 1998 [29]. Further, hydroxyurea received US FDA approval for the treatment of children (pediatric patients) from 2 years of age and older with severe SCA in 2017.
The clinical studies of hydroxyurea pluripotency to induce fetal hemoglobin (HbF) in sickle cell anemia started in the mid- 1980s [51,52],
followed by the phase I/II [53], phase III/MSH [54], and BABY HUG [55]
trials which led to its approval in adults ﬁrst- 1998 and then
children-2017 (Table 1). These approvals were granted to reduce the
frequency of painful crises and the need for blood transfusions in both
children and adults of SCA with recurrent moderate to severe painful
crises.
The pharmacological interventions of hydroxyurea for SCA relate to
its ability to increase fetal hemoglobin (HbF) levels. The HbFcontaining γ-globin chain is the principal hemoglobin found during
the pregnancy period of the individual. Six weeks after birth, the HbF is
replaced by the adult hemoglobin containing the Beta-globin chain.
Hydroxyurea adopts a mechanism of action that favors a continued
production of the fetal hemoglobin instead of the adult hemoglobin
whose Beta-globin gene becomes abnormal over time. Therefore, HU
can elevate HbF levels, which in turn inhibits/retards HbS polymerization. Hydroxyurea has multiple mechanisms of action and profound
beneﬁts in responders [29]. Although, the exact mechanisms of action
of hydroxyurea remain incompletely understood. However, some of
these mechanisms of action have been elucidated [56, 57]. The most
signiﬁcant mechanism of action is the reversible inhibition of ribonucleotide reductase, followed by the signal transduction pathway (Figures 3 and 4). Several reviews have claimed that hydroxyurea might
work by mechanisms beyond its effects on HbF and that its full beneﬁts
in SCA are multifactorial [48, 58]. Piccin and associates further summarized the seven most relevant modes of action of hydroxyurea [27].
Some of these possible mechanisms of action show signiﬁcant impact
on the erythrocyte cation transport (improvement in RBC hydration),
sickle cell membrane, adhesion molecules (reduction of neutrophil
count, leukocyte adhesion, and pro-inﬂammatory markers), NO generation, erythropoietin production, and red cell deformability [59, 60,
61, 62, 63, 64].

3.3. Crizanlizumab (Adakveo)
The US FDA approved crizanlizumab for sickle cell patients above
16 years of age in November 2019. Crizanlizumab is a humanized
monoclonal antibody targeted against the vaso-occlusion pathway to
attenuate vaso-occlusion crisis. It binds with P-selectin to inhibit Pselectin interaction with other adhesion molecules-neutrophils, platelets, and activated erythrocytes in the endothelial (Figure 6). In a
recent study trial conducted by [70, 71], crizanlizumab demonstrated
a signiﬁcant reduction in the episodic crisis experienced by sickle
cell patients compared with the placebo group with or without
hydroxyurea.
3.4. Voxelotor (Oxbryta/GBT440)
Voxelotor was approved by the FDA in November 2019, for the
treatment of SCD patients 12 years of age and older. Voxelotor is a hemoglobin modulator, thus increasing hemoglobin levels. It binds to the
N- terminal valine of the alpha subunit of hemoglobin and increases its
afﬁnity for oxygen [72]. The increased afﬁnity of the sickle cell hemoglobin for oxygen stabilizes the hemoglobin and prevents polymerization
(sickling) [73]. Recent studies conducted during trials showed a concurrent rise in hemoglobin levels and a signiﬁcant reduction in the
markers of hemolysis (unconjugated bilirubin, percentage of reticulocytes, except LDH) and the percentage of sickled red cells when
offered voxelotor (Table 1) [74, 75]. Voxelotor is generally well tolerated
and safe with moderate adverse outcomes-headache, diarrhea, nausea,
and arthralgia [76]. Patients who are hydroxyurea resistant with
continuous hemolysis and anemia may consider a voxelotor supplement
as an additional agent.

3.2. L-glutamine (Endari)
The L-glutamine oral powder (Endari) is the second drug approved in
July 2017 by the Food and Drug Administration for the treatment of
complications of SCD in 5 years and older individuals [25, 49]. Several
studies and extensive reviews have shown oxidative stress to be a critical
factor in the pathophysiology of SCD. The mechanism of action of

4. Nutrition and sickle cell disease
Nutrition plays a signiﬁcant role in children with SCD; however its
importance tends to be overruled due to the preference given to the
5

O.J. Alabi et al.

Heliyon 8 (2022) e09630

Figure 3. HU Mechanism of Action via the Epigenetic and Post Transcriptional Modiﬁcation: HU inhibits ribonucleotide reductase, the enzyme that converts
ribonucleosides (NDP) into deoxyribonucleosides (dNDP). dNDP is required for the synthesis and repair of DNA. Therefore, the inhibition of this enzyme impedes the
progression of cellular division (DNA synthesis) through the S-phase, thereby altering erythroid kinetics and causing a reversal via a recovery phase of hematopoietic
precursors. This indirect remodeling enhances the recruitment of early erythroid progenitors (such as stress erythropoiesis), which silence the epigenetic signals/
enzymes and induce Y-globin expression. HU can also remodel Y-globin gene loci by directly repressing the epigenetic enzymes. DNA methyltransferase 1 (DNMT1);
various histone deacetylases (HDAC), lysine demethylase 1 (LSD1, KDM1A); chromodomain helicase DNA binding protein 4 (CHD4); SWI/SNF-related matrixassociated actin-dependent regulator of chromatin subfamily A member 5 (SMARCA5); DNA-binding factors DRED (TR2/TR4); BCL11A: B-cell CLL/lymphoma 11A
(BCL11A); Hemoglobin subunit gamma-1 & 2 (HBG1/HBG2) Adapted from [56].

associated with hypophagia in both sickle cell children and adults during
steady states [79].
12 weeks after birth, sickle children develop lower weight (wasting)
and height (stunting), which persists through adolescence and adulthood. Both wasting and stunting are usually associated or linked with/to
poor nutritional status, impaired growth and immune functions. Children
with SCD have been indicated to manifest different degrees of macro- and
micro-deﬁciencies, which is associated with SCD painful crises and the
frequency of hospitalizations [82, 83]. Nutritional supplementation with
polyunsaturated fatty acids, magnesium, iron, zinc, folate, protein, energy, vitamin A, C, D and E, have all been suggested with the great

clinical predictors of SCD morbidity including dactylitis prior to age 1, a
haemoglobin <7 g/dL and leukocytosis [79]. In a steady state, a sickle
cell patient is most likely to experience a signiﬁcant reduction in energy
intake and a signiﬁcant increase in energy expenditure during crises. This
is probably due to the increased in metabolic demands driven by protein
and bone turnover caused by chronic hemolysis, resting metabolic rate,
glucose and lipid ﬂuxes, thus producing a negative energy balance and
undernutrition [79, 80]. According to a study from Heyman and associates [81], it is easier to speculate a priori that the reason for low dietary
and energy intake may be due to a loss of appetite from the early stage of
life. Additionally, proinﬂammatory mediators-cytokines - are likely to be
6
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Figure 4. Hu Mechanism of Action Via the Signaling Pathway: NO: nitric oxide; sGC: soluble guanylyl cyclase; GTP: guanosine triphosphate; cGMP: cyclic
guanosine monophosphate; p38 MAPK: p38 mitogen-activated protein kinase; SOX6: SRY-Box Transcription Factor 6; LF1: Kruppel Like Factor 1; T-ALL: T-cell acute
lymphoblastic; BCL11A: B-cell CLL/lymphoma 11A. Adapted from [57].

SCD has created many gaps for recent research with many clinical trials
trying to reduce the complications and pain episodes that may result
from SCD.
According to ((FAO), 2007), Functional food is any food with physiological beneﬁts, and capable of reducing the risk of chronic disorder
beyond the normal nutritional trait such food possesses. More so, it is said
to be the food that provides and equips the body with wealthy health
((FAO), 2007). Nutraceuticals as explained by Ferrari [85] is also a food
or part of foods that has clinical beneﬁts, and capable of preventing/treating few or many disorders. Countries like Nigeria still face the
increased rate of SCD crises in children, and the different strategies
erected to manage the crises are narrowly unavailable for every individual due to the cost in procuring them (Table 1). This review elucidates
the adoption of the functional foods and nutraceuticals as one of the
therapies or adjuvants of treatment to manage SCD diseases in Nigerian
children. This is because functional foods are readily available and occur
naturally in edible medicinal plants’ seeds, fruits, leaves or their
cooked/extracts.

potential beneﬁt of preventing the painful crises of SCD and promoting
healthy growth in children with SCD [84]. Therefore, there is the need to
consider the roles of different nutrients and integrate nutritional interventions in the management of children with SCD.
5. Functional foods and nutraceuticals as adjunct therapies in
managing SCD
The terms “Functional foods” and “Nutraceuticals” have become
popular in the scientiﬁc world, and mostly adopted in twenty ﬁrst
century by the food and nutritional researchers who are currently
working on how to solve various crises arising from the degenerative
diseases, and some genetically triggering diseases like sickle cell diseases. The terms have been used in many reviews and articles with the
aim to stress the importance of foods in mitigating diseases. At the
molecular level, functional foods and nutraceuticals are said to bring
about some interactions which are due to the bioactive components or
ingredients present in these compounds (Figure 7 & Table 2). Managing
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Figure 5. Proposed Mechanism of Action for L-glutamine: GA: glutamine aminohydrolase; aKG: A-ketoglutarate; NADS: nicotinamide adenine dinucleotide synthase;
G6P: Glucose 6-phosphate; G6PD: Glucose 6-phosphate dehydrogenase; Enzyme 1; Y-glutamyl cysteine synthetase; Enzyme 2: glutathione synthetase; 6-PGL: 6Phosphogluconolactone; GSH: Reduced Glutathione; GSSH: Oxidized Glutathione. Adapted from [65].

found to include albumin, globulin, and phenolic chemicals, all of which
have strong antioxidant characteristics [21, 86]. These chemicals have
antisickling properties and can reduce oxidative stress, which is linked to
the SCD crisis. According to a study, individuals in Cameroon's West
Region frequently use black bean seed varieties to treat SCD [88]. The
bioactive chemicals contained in bean products have been reported to

5.1. Antisickling effects
Black beans are generally used as a source of plant proteins [86], and
they come in a variety of seed shapes, sizes, and colors all over the world
(Figure 8a). Black beans contain a total of 16 amino acids with a variety
of health effects, according to HPLC proﬁling [87]. Bean products are

Figure 6. Mechanism of action of Crizanlizumab. P-selectin is predominantly expressed on the endothelial cells and platelets. Adapted from [https://www.creati
vebiolabs.net].
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Figure 7. Graphical summary of actions of some functional foods.

Table 2. Main Functions of Functional Foods and their Correlations with FDA-Approved Drugs during Sickle Cell Crisis.
S/N

Functional Foods

Bioactive Compounds

FDA-Approved
Pharmaceutical Drugs

Main Functions

1

Black Beans (Phaseolus vulgaris L.)

Amino acids [22]

L-glutamine
Hydroxyurea
Voxelotor

Targeting HbS polymerization: Antisickling effect,
membrane stability, and Antioxidant potentials [21, 86]

2

Aged Garlic (Allium sativum)

Flavonoids, Organosulfur [108]
and Amino acids [109]

L-glutamine

Targeting hemolysis-mediated endothelial
dysfunction: Antioxidant potentials [104]

3

Bitter Kola (Garania kola H.)

Phenolic compounds such as:
Tannins, Guttiferin, Flavonone,
etc. [98]

Crizanlizumab

Targeting vasocclusion: modulate inﬂammatory
responses (Membrane stability) [100]

4

Broccoli (Brassica oleracea)

Vitamin A [92]

Crizanlizumab

Targeting vasocclusion: Membrane stability and
protective [99]

5

Kiwi (Actinidia deliciosa)

Vitamin C
Vitamin E [92]

L-glutamine

Targeting hemolysis-mediated endothelial
dysfunction: boost the glutathione antioxidant defense
system thereby promoting Antisickling and therapeutic
properties [92]

6

Walnuts (Juglans regia); Flax seeds
(Linum usitatissimum); Chia seeds
(Salvia hispanica)

Omega – 3 fatty acids [112, 113]

Crizanlizumab
L-glutamine

Targeting vasocclusion: Anti-adhesive, antiagreggatory and anti-inﬂammatory properties [114]

interaction required for gelation [91]. These observations suggest that
black beans could be a promising anti-sickling, membrane stability, and
antioxidant agent in the treatment of SCD.
Another functional food with antisickling properties is kiwi fruit
(Figure 8b). Kiwi is rich in both vitamin C and E [92]. Dietary supplementation with Kiwi as given by [92], maybe an important adjunct
during SCD therapy. Antioxidant vitamins C and E can boost the glutathione antioxidant defense system and exhibit an inhibitory role in red
blood polymerization [2]. Its combination with anti-SCD therapeutic
drugs has been reported to reduce the incidence and severity of sickle cell
crisis [93]. In the ﬁndings of Kawchak and colleagues [94], functional
foods containing vitamins E and C have the propensity to improve the
health conditions of SCD children. The effects of these vitamins have
been shown to decrease arterial blood pressure, mean corpuscular hemoglobin levels, and irreversible sicklde cells [2]. Vegetable and fruit
diets such as kiwi may contain vitamin C and E [92] with a great antisickling property and therapeutic beneﬁts in sickle cell anemia management cases [95].

protect against cardiovascular disease and cancer, and other chronic
diseases in various studies [89, 90]. Their antioxidant activity and capacity to chelate metal catalysts are the reasons for this [21].
The reduction in the Fe2þ/Fe3þ ratio, as previously stated, is one of
the downstream events that occurs during polymerization in sickle cells.
Polymerization causes ferrous iron (oxyhemoglobin-Fe2þ) to oxidize to
ferric iron (methemoglobin-Fe3þ), preventing oxygen ﬁxation. The
antioxidant, antisickling, and membrane stability capabilities of black
bean components have all been studied [87]. The ﬁndings reveal a rise in
Fe2þ/Fe3þ ratio, DPPH/OH* scavenging effect, and a considerable
reduction in HbS polymerization and hemolysis, all of which are related
to the distinct roles of both L-glutamine and hydroxyurea. The presence
of antioxidant amino acids in black beans may explain why they can
inhibit ferrous iron oxidation and so boost sickle cell hemoglobin's afﬁnity for oxygen in individuals with SCD, similar to how voxelotor
works. Furthermore, some of these amino acids' polar/hydrophobic
character is thought to have assisted their capacity to diffuse into the HbS
molecule and bind at the heme pocket, preventing the protein-protein
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Figure 8. Pictures of Functional Foods: (a) Black beans (Phaseolus vulgaris L); (b) Kiwi (Actinidia deliciosa); (c) Bitter kola (Garania kola H.): (d) Broccoli (Brassica
oleracea); (e) Aged garlic (Allium sativum); (f) Walnuts seeds (Juglans regia); (g) Flax seeds (Linum usitatissimum) (h) Chia seed (Salvia hispanica). (Listed functional
foods were purchased from local market in Borg El Arab, Egypt).

decreasing Heinz bodies. Similarly, AGE has been reported to inhibit
dense cell formation (dense bodies) in vitro and ex vivo [111]. The high
level of amino acids, S-allyl cysteine, and antioxidant vitamins identiﬁed
in AGE must have contributed to the erythrocyte deformability and
antisickling potency of garlic in the management of SCD.

5.2. Membrane stability
Bitter kola is a medicinal seed with an abundance of biologically
active products (Figure 8c). An ethnobiological survey has shown that
some families in Oyo State, Nigeria [96] and in the Littoral region of
Cameroon [88] are fond of using bitter kola for the management of SCD.
Bitter kola seeds have been reported to contain several phenolic compounds such as guttiferin, tannins [97], garcinia ﬂavanone, xanthenes,
benzophenone, kolaﬂavanone, and biﬂavonoids [98]. These chemical
constituents possess antibacterial, antiviral, and anti-inﬂammatory
properties [99], which could prevent infections and modulate inﬂammatory responses in SCD. An investigative study on bitterkola seed
conﬁrmed that it was more effective in stabilizing erythrocyte membranes as seen/observed in HbAA, HbAS, and HbSS genotypes [100].
More so, antioxidant fruits and vitamins are protectors and maintainers of the membrane structure of RBCs, preventing them from being
depleted by free moving radicals during SCD. Broccoli [91] (Figure 8d) is
one of the functional foods that provide Vitamin A, an effective substance
that improves iron absorption during RBCs formation and differentiation
by increasing the mobilization of iron from the tissue stores. It also enhances erythropoiesis and immunity [101]. In the study of Boadu, intake
of Vitamin A in children with SCD has signiﬁcant importance and improves their health [102]. This result also supports the ﬁndings of [103].

5.4. Anti-adhesive, anti-aggregatory and anti-inﬂammatory properties
Walnuts, Flaxseeds, and Chia seeds (Figure 8f) may be another
important dietary supplement for SCD crises. Omega – 3 fatty acids [112]
present in walnuts, Flaxseeds, and Chia seeds [92] as reported by Daak
and colleagues [113] play a signiﬁcant role in improving the overall
health of children with SCD by reducing vaso-occlusive crisis. This is
probably due to its anti-adhesive, anti-aggregatory, vasodilatory and
anti-inﬂammatory properties [114]. Synthesis and repair of the red blood
cell membrane (RBCM) require omega – 3 and omega- 6 fatty acids which
are collectively called polyunsaturated fatty acids (PUFAs). Lack of foods
rich in PUFAs may cause defects in the repair system of the RBCM, thus
retarding the neural maturation and development, and some other sensory systems. Recent studies have explained the role of sickle
vasculopathy-vascular inﬂammation and thrombosis-in the generation of
sickle cell complications [115, 116, 117]. Recently, sickle cell mice
studies have demonstrated that supplementation with Omega – 3 fatty
acid diet normalizes RBC membrane, improves NO production, reduces
inﬂammation and adhesion molecules [118]. With the above features,
one might hypothesize that Omega – 3 fatty acids expresses/possesses the
unique activity of crizanlizumab and L-glutamine. Therefore the higher
the level of Omega – 3 fatty acids in the blood, the lower the risk of
complications or severe symptoms of SCD, and the lesser the degree of
anemia [119].

5.3. Antioxidant potential
Aside antioxidant fruits, garlic has been declared a versatile vegetable
with great antioxidant potentials [104] (Figure 8e). The bioactive compounds [105] in garlic are highly effective against peroxidation and free
radicals that often cause damage to cells and organs. Aged garlic extract
(AGE) has been proclaimed to be safer [106] and exerts potent antioxidant effects in vitro and in vivo compared to fresh garlic [93, 107]. It
enhances antioxidants levels in the body (ascorbic acid, vitamin E,
reduced glutathione (GSH), glutathione peroxidase (GPx), superoxide
dismutase (SOD), and catalase). The ﬂavonoid and the organosulfur
component of garlic prevent blood clots and keep blood vessels ﬁt [108].
According to a study by Nwaoguikpe [109], the proximate composition
and phytochemical proﬁle of garlic comprise 18 amino acids and vitamin
C. Another study evaluated the antioxidant effect of AGE on RBCs via
Heinz body analysis [110]. In the above studies, AGE inhibited the
polymerization process, stabilized and improved the oxidant status of the
erythrocyte membranes by improving the Fe2þ/Fe3þ ratio and

5.5. Seed, leaf and root extracts of plants
Many medicinal roots, leaves, and seeds that contain beneﬁcial
phytochemical compounds have been utilized since the onset of SCD to
reduce sickling and painful occurrences. Leaf extracts of Carica papaya
and Parquetina nigrescens, root extracts of Fagara zanthoxyloides, and seed
extracts of Cajanus cajan are antioxidant plant extracts, which also play
vital roles as antisickling agents [2]. In vitro research on extracts of Carica
papaya leaves has indicated its potency in reducing hemolysis and preserving erythrocyte membrane integrity [9, 120]. Similarly, the extract of
Parquetina nigrescens exerts anti-sickling activities and confer protection
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Department of Biochemistry, University of S~ao Paulo Brazil), for
assisting with the illustration.

on the integrity of the RBC membrane [121]. Another study conducted
on a cocktail of Carica papaya, Parquetina nigrescens, and Fagara zanthoxyloides extracts shows promising results [122]. These pharmacological properties are due to the presence of several phenolic compounds
and free amino acids found in these plant extracts [123, 124, 125].
Eugenia caryophyllata and Piper guineense are other examples of medicinal
plants thatcontain vanilloids like Shikimic acid and cannaboids that are
of beneﬁt in reducing the painful symptoms of SCD [126]. Additional
phytomedicines that have been reported to possess antisickling potentials are Pterocarpa osun, Justicia secunda, and Sorghum bicolor extracts
[127,128].
Taken together, these functional foods can be used in the form of food
or decoction. The consumption of a cocktail of functional foods is highly
recommended for sickle cell disease patients. Consuming functional
foods and nutraceuticals alongside with/without FDA-approved drugs
can be one of the ﬁrst–line and promising therapies in managing the
crises of SCD in Nigerian children especially during their infanthood
stages.
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